FMT

New research from the University of Virginia School of Medicine sheds light on why a fecal transplant can benefit patients with dangerous recurrent C. difficile infections – and suggests a way to improve patient outcomes.

Experts reflect on the barriers to utilizing fecal microbiota transplantation therapy in Clostridioides difficile infection.

Researchers have proposed a more detailed explanation as to why faecal microbial transplants (FMT) from a healthy donor can improve outcomes in patients with Clostridioides difficile infection (CDI).

This study brings new data in supporting the FMT role in CDI treatment, including the primary severe CDI, however, further prospective and controlled studies on larger cohorts should be performed in this respect.

The data regarding the safety and efficacy of fecal microbiota transplantation for patients with C difficile infections and inflammatory bowel disease has been limited.

Experts focus on the current state of fecal microbiota transplant as a treatment option for clostridium difficile infection.

Oral lyophilized fecal microbiota transplantation following antibiotic use induced and maintained remission in patients with active ulcerative colitis, according to research published in Lancet Gastroenterology and Hepatology. “FMT delivered via colonoscopic infusion and enemas induces clinical remission in 24% to 47% of patients with active ulcerative colitis. However, this route of

The panel considers optimal therapy for recurrent CDI, particularly the role of fecal microbiota transplantation.

Nature Medicine - FMT for patients with cancer

Research from the University of Virginia School of Medicine sheds light on why fecal transplants benefit patients with recurrent C. difficile infections.

FMT appears to be a highly effective therapy for preventing recurrent CDI in patients with IBD. Patients who fail a single FMT may benefit from multiple FMTs.

What is it like to get #FMT for #IBD?@JelenaPopov02 et al talked to kids with IBD who received FMT enemas and their parents:💩 Fear of discomfort before FMT 💩 "Not a big deal" after FMT💩 FMT was a "natural treatment" but less convenienthttps://t.co/OXIVGAzzgh pic.twitter.com/OUVrk1pWu3— JPGN (@JPGNonline) November 26, 2021

sease care. To date, no studies have assessed FMT acceptance among pediatric patients who underwent FMT treatment. Here, we explored the perceptions and experiences of FMT in a population of pediatric UC patients who participated in a recent FMT pilot randomized controlled trial. Methods: Children who received bi-weekly FMT treatments for 6 weeks through a clinical trial (NCT02606032) and their parents participated in face-to-face, semi-structured interviews led by study investigators. Interviews were audiotaped, transcribed, and analyzed using validated qualitative research methods. Results: Eight patients and eight parents were interviewed, with qualitative data summarized across four themes and 11 subthemes. The majority of participants perceived FMT as a “natural treatment” and cited lack of response to conventional medications and fear of medication side-effects as motivators for pursuing FMT. Pre-treatment, patients and parents expressed concerns regarding physical discomfort with FMT administration; post-treatment, most patients reported feeling “completely normal.” Both patients and parents uniformly expressed interest in pursuing FMT again in the future if available. Convenience of medication therapies, and perceived naturality and efficacy of FMT were all endorsed. Conclusions: This is the first study to describe pediatric and parent experiences receiving FMT. This information is valuable to develop and encourage future FMT trials involving children. Pre-treatment, concerns about FMT were common. Post-treatment, patients reported tolerance to FMT and a desire to continue receiving this therapy if available. Further trials of FMT in UC are needed. Investigators should include pediatric patients without concern of acceptance....

Fecal microbiota transplantation (FMT) is a new and adequate route to modify the microbial ecosystem in gastrointestinal tract of the hosts. Intestina…

Based on the selected studies, the AE rate of FMT is 39.3%, with most AE being mild and self-limiting. SAE were uncommon at 5.3%, and many were only possibly related to the FMT. Adherence to standardized reporting of AE as well as longitudinal studies and registries will help further clarify the saf …

/PRNewswire/ -- Our gut houses billions of different microbes, each serving its purpose to keep our gut functioning and healthy. The Clostridioides difficile...

Scientists suggest that older mice given gut bacteria transplants from younger mice show learning and memory abilities similar to those of the younger rodents.

Success of engraftment in FMT can be assessed using NGS and metagenomic analysis and parallels success in curing CDI of the microbiome. The statistical methods we present here are reliable and consistent for such purposes. The dissimilarity of Pt. 3 to the donor combined with the failure of engraftm …

AbstractBackground. Children with inflammatory bowel disease (IBD) are disproportionally affected by recurrent Clostridioides difficile infection (rCDI). Althou

According to a French-Italian study, the efficacy and safety of fecal microbiota transplant have been confirmed for the treatment of multi-drug resistant bacterial infections, even in immunocompromised patients.

(2021). Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. Gut Microbes: Vol. 13, No. 1, 1979878.

In this episode of Bowel Sounds, hosts Drs. Temara Hajjat and Jennifer Lee talk to Dr. Stacy Kahn about fecal microbiota transplantation (FMT) in children with GI disorders. We discuss indications, contraindications, safety, methods of delivery, o...

Vulnerable patients with intestinal colonisation of multidrug-resistant organisms (MDROs) are recognised to be at increased risk of invasive MDRO driv…

Dr. Cathy Williams knew something wasn’t right. The veterinarian had felt off for weeks after her 2014 trip to Madagascar. At first she just felt bloated and uncomfortable and wasn’t interested in eating much. But eventually she developed a fever and chills that sent her to the emergency room. When tested, doctors found that what […]

Autism spectrum disorder (ASD) is a severe brain development disorder that is characterized by deficits in social communication and restricted, repetitive and stereotyped behaviors. Accumulating evidence has suggested that gut microbiota disorders play important roles in gastrointestinal symptoms and neurodevelopmental dysfunction in ASD patients. Manipulation of the gut microbiota by fecal microbiota transplantation (FMT) was recently shown to be a promising therapy for the treatment of various diseases. Here, we performed a clinical trial to evaluate the effect of FMT on gastrointestinal (GI) and ASD symptoms and gut microbiota alterations in children with ASD. We found that there was a large difference in baseline characteristics of behavior, GI symptoms, and gut microbiota between children with ASD and typically developing (TD) control children. FMT could improve GI symptoms and ASD symptoms without inducing any severe complications. Similarly, FMT significantly changed the serum levels of neurotransmitters. We further observed that FMT could promote the colonization of donor microbes and shift the bacterial community of children with ASD toward that of TD controls. The abundance of Eubacterium coprostanoligenes pre-FMT was positively correlated with high GSRS scores, whereas a decrease in Eubacterium coprostanoligenes abundance induced by FMT was associated with the FMT response. Our data suggest that FMT might be a promising therapeutic strategy to improve the GI and...

Based on the findings from this large US multi-center cohort, the efficacy of FMT for the treatment of rCDI did not differ in children with IBD. Failed FMT among children with IBD was possibly related to the presence of clinically active IBD.